Exploring Off-Label Use of Drugs and the FDA Approval Process

The struggle over how best to address COVID-19 has become increasingly partisan. The public fight over the value of hydroxychloroquine as a helpful treatment should be (but isn't) driven by the evidence, according to Cato's Jeff Singer.

---

Hosted on Acast. See acast.com/privacy for more information.